March 24, 2017 / 12:50 PM / 10 months ago

BRIEF-Oncology Venture to evaluate Eisai oncology drug for in-license to 2X Oncology Inc.

March 24 (Reuters) - Oncology Venture Sweden AB:

* Oncology Venture Sweden AB and Eisai Inc. (Woodcliff Lake, NJ U.S.A.) have entered an agreement under which Oncology Venture will develop a Companion Diagnostic (utilizing its proprietary Drug Response Predictor (DRP) technology) for an undisclosed Eisai oncology therapeutic agent in order to evaluate its interest in in-licensing the drug for further clinical development in the OV spin-out, 2X Oncology Inc. (Boston, MA U.S.A.)

* The drug is Phase 2 stage, the targeted small molecule inhibitor having promising application in a number of human cancers

* If the DRP evaluation is successful, OV may exclusively in-license the drug for further development within and by 2X Oncology Inc

Source text:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below